Filing Flows › Metagenomi Therapeutics (MGX) › How it makes money
How Metagenomi Therapeutics (MGX) makes money
Metagenomi Therapeutics (MGX) made $1.2M of revenue in the first quarter 2026 (Q1 2026), -70% from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q1 2026 | % of revenue |
|---|---|---|
| Revenue | $1.2M | 100.0% |
| Income tax | $10K | 0.8% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q1 2026 | $1.2M | -70% |
| Q4 2025 | $3.9M | -59% |
| Q3 2025 | $8.7M | -25% |
| Q2 2025 | $8.5M | -58% |
| Q1 2025 | $4.1M | -63% |
| Q4 2024 | $9.6M | -22% |
From Metagenomi Therapeutics' 10-Q filed May 11, 2026 (on EDGAR).
Questions
How does Metagenomi Therapeutics make money?
Metagenomi Therapeutics (MGX) made $1.2M of revenue in the first quarter 2026 (Q1 2026), -70% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.